UNSPSC 51351619: Estradiol acetate

This classification denotes an estrogen C20H26O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5R97F5H93P, chemically known as estra-1,3,5(10)-triene-3,17-diol, (17.beta.)-, 3-acetate, but more generally known as estradiol acetate, which bears US NIH Compound Identifier 157050. European Medicines Agency schedules Estradiol acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB27089. Most nations, for tariff and trade purposes, schedule estradiol acetate under HS 29372300 and SITC 54153.

As of Q4 2014, ESTRADIOL ACETATE remains US FDA's Preferred Term for this commodity. Estradiol acetate bears US NLM identifiers UMLS ID C1330622 and NCI Concept Code C47990. SMILES: CC(=O)OC1CCC2C(C1)CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4O)C.

UNSPSC 51351619 Estradiol acetate is a Commodity code representing pharmaceutical products sold to state and local government health systems through cooperative purchasing vehicles. State and local procurement under this code consists of generic and over-the-counter pharmaceuticals acquired via multi-state cooperative contracts that require manufacturers to supply products through authorized wholesalers with specific pricing models, regulatory certifications, and supply-chain security compliance. Issuing bodies include state health and human services departments and state purchasing offices that administer cooperative purchasing alliances spanning multiple participating states and local government facilities. The procurement model emphasizes vendor qualification on manufacturing standards, wholesale distribution capability, pricing flexibility, and insurance coverage rather than open competition among individual hospitals or clinics.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota, Oregon, and other alliance member jurisdictions. The RFP requires vendors to hold current Good Manufacturing Practice certification and Drug Supply Chain Security Act compliance, maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, Morris & Dickson Co.), and accept a 3 percent administrative fee on all purchases. Evaluation weights pricing competitiveness at 75 percent, with the remaining 25 percent distributed across fixed pricing, administrative compliance, EDI capability, and fee acceptance. Contract awards are effective July 1, 2026, with a two-year term for new responders and optional MMCAP extensions.